Quijada-Álamo Miguel, Hernández-Sánchez María, Robledo Cristina, Hernández-Sánchez Jesús-María, Benito Rocío, Montaño Adrián, Rodríguez-Vicente Ana E, Quwaider Dalia, Martín Ana-África, García-Álvarez María, Vidal-Manceñido María Jesús, Ferrer-Garrido Gonzalo, Delgado-Beltrán María-Pilar, Galende Josefina, Rodríguez Juan-Nicolás, Martín-Núñez Guillermo, Alonso José-María, García de Coca Alfonso, Queizán José A, Sierra Magdalena, Aguilar Carlos, Kohlmann Alexander, Hernández José-Ángel, González Marcos, Hernández-Rivas Jesús-María
Servicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
J Hematol Oncol. 2017 Apr 11;10(1):83. doi: 10.1186/s13045-017-0450-y.
Chronic lymphocytic leukemia (CLL) is a highly genetically heterogeneous disease. Although CLL has been traditionally considered as a mature B cell leukemia, few independent studies have shown that the genetic alterations may appear in CD34+ hematopoietic progenitors. However, the presence of both chromosomal aberrations and gene mutations in CD34+ cells from the same patients has not been explored.
Amplicon-based deep next-generation sequencing (NGS) studies were carried out in magnetically activated-cell-sorting separated CD19+ mature B lymphocytes and CD34+ hematopoietic progenitors (n = 56) to study the mutational status of TP53, NOTCH1, SF3B1, FBXW7, MYD88, and XPO1 genes. In addition, ultra-deep NGS was performed in a subset of seven patients to determine the presence of mutations in flow-sorted CD34+CD19- early hematopoietic progenitors. Fluorescence in situ hybridization (FISH) studies were performed in the CD34+ cells from nine patients of the cohort to examine the presence of cytogenetic abnormalities.
NGS studies revealed a total of 28 mutations in 24 CLL patients. Interestingly, 15 of them also showed the same mutations in their corresponding whole population of CD34+ progenitors. The majority of NOTCH1 (7/9) and XPO1 (4/4) mutations presented a similar mutational burden in both cell fractions; by contrast, mutations of TP53 (2/2), FBXW7 (2/2), and SF3B1 (3/4) showed lower mutational allele frequencies, or even none, in the CD34+ cells compared with the CD19+ population. Ultra-deep NGS confirmed the presence of FBXW7, MYD88, NOTCH1, and XPO1 mutations in the subpopulation of CD34+CD19- early hematopoietic progenitors (6/7). Furthermore, FISH studies showed the presence of 11q and 13q deletions (2/2 and 3/5, respectively) in CD34+ progenitors but the absence of IGH cytogenetic alterations (0/2) in the CD34+ cells. Combining all the results from NGS and FISH, a model of the appearance and expansion of genetic alterations in CLL was derived, suggesting that most of the genetic events appear on the hematopoietic progenitors, although these mutations could induce the beginning of tumoral cell expansion at different stage of B cell differentiation.
Our study showed the presence of both gene mutations and chromosomal abnormalities in early hematopoietic progenitor cells from CLL patients.
慢性淋巴细胞白血病(CLL)是一种高度基因异质性疾病。尽管CLL传统上被认为是一种成熟B细胞白血病,但很少有独立研究表明基因改变可能出现在CD34+造血祖细胞中。然而,同一患者CD34+细胞中染色体畸变和基因突变同时存在的情况尚未得到探究。
对通过磁珠激活细胞分选分离出的CD19+成熟B淋巴细胞和CD34+造血祖细胞(n = 56)进行基于扩增子的深度二代测序(NGS)研究,以研究TP53、NOTCH1、SF3B1、FBXW7、MYD88和XPO1基因的突变状态。此外,对7例患者的亚组进行超深度NGS,以确定流式分选的CD34+CD19-早期造血祖细胞中是否存在突变。对该队列中9例患者的CD34+细胞进行荧光原位杂交(FISH)研究,以检查细胞遗传学异常情况。
NGS研究在24例CLL患者中共发现28个突变。有趣的是,其中15例在其相应的整个CD34+祖细胞群体中也显示出相同的突变。大多数NOTCH1(7/9)和XPO1(4/4)突变在两个细胞组分中呈现相似的突变负荷;相比之下,与CD19+群体相比,TP53(2/2)、FBXW7(2/2)和SF3B1(3/4)的突变在CD34+细胞中显示出较低的突变等位基因频率,甚至没有。超深度NGS证实了CD34+CD19-早期造血祖细胞亚群(6/7)中存在FBXW7、MYD88、NOTCH1和XPO1突变。此外,FISH研究显示CD34+祖细胞中存在11q和13q缺失(分别为2/2和3/5),但CD34+细胞中不存在IGH细胞遗传学改变(0/2)。综合NGS和FISH的所有结果,得出了CLL中基因改变的出现和扩展模型,表明大多数基因事件出现在造血祖细胞上,尽管这些突变可能在B细胞分化的不同阶段诱导肿瘤细胞扩增的开始。
我们的研究表明CLL患者早期造血祖细胞中存在基因突变和染色体异常。